Matinas BioPharma
MTNB
18 hedge funds and large institutions have $1.97M invested in Matinas BioPharma in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 31 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
25.99% more ownership
Funds ownership: 0.31% → 26.3% (+26%)
63% less funds holding
Funds holding: 48 → 18 (-30)
68% less capital invested
Capital invested by funds: $6.15M → $1.97M (-$4.18M)
94% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$4.83M |
| 2 |
Squarepoint
New York
|
+$131K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$66.2K |
| 4 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
+$62.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$534K |
| 2 |
AWMG
Alliance Wealth Management Group
Flemington,
New Jersey
|
-$299K |
| 3 |
TCM
Towercrest Capital Management
Newtown,
Pennsylvania
|
-$299K |
| 4 |
NRS
Neville Rodie & Shaw
New York
|
-$183K |
| 5 |
LPL Financial
San Diego,
California
|
-$96.9K |
MTNB Hedge Fund Activity: Q3 2024 in Review
18 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2024, worth a combined $1.97M — down 68% from $6.15M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of MTNB and 2 opened new positions — a net loss of 29 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $4.83M. The largest seller was Highbridge Capital Management, cutting an estimated $534K.
- 18 institutional investors held Matinas BioPharma (MTNB) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $1.97M of Matinas BioPharma stock for Q3 2024, down 68% quarter-over-quarter.
- 2 funds opened new Matinas BioPharma positions in Q3 2024 and 31 closed out, a net change of -29 holders.
- The largest Matinas BioPharma buyer in Q3 2024 was JTC Employer Solutions Trustee, an estimated $4.83M added.
- The largest Matinas BioPharma seller in Q3 2024 was Highbridge Capital Management, an estimated $534K sold.
Based on aggregated 13F filings for Q3 2024.